CorMedix
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
300 Connell Dr Ste 4200, Berkeley Height...Phone Number
(908) 517-9500Website
www.cormedix.comRevenue
$462.2 MillionStock Symbol
CRMDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Explore more
CorMedix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CorMedix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on CorMedix recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if CorMedix had a recent Job posting/layoffs
Product Launch: Get notified when CorMedix launches new products
CorMedix, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if CorMedix is spiking on competitors!
Check if CorMedix has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once CorMedix has new funding data
Congratulate Masked Content for being promoted to Masked Content at CorMedix
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to CorMedix
Compare insights from companies similar to CorMedix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CorMedix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CorMedix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CorMedix.
CorMedix financials insights
Gather financial insights about CorMedix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Stock Offering
$12.5M
CorMedix Tech Stack
A closer look at the technologies used by CorMedix
Most Recent Scoops
Person-Based
Business Development, Contracts
Earnings
CorMedix has reported selling and marketing expenses of $12.4 million in Q2 2026, an increase of approximately 95% from $6.4 million in Q2 2025, driven primarily by higher personnel costs associated with a larger product portfolio and related marketing programs.
Earnings, Spending/Investment, Marketing Campaign, Finance
Project
CorMedix has announced that the ReSPECT Study met its primary FDA endpoint of fungal-free survival at day 90, demonstrating non-inferiority versus the standard antifungal regimen and meeting the pre-specified non-inferiority margin, with a favorable profile also observed across multiple secondary endpoints including treatment-emergent adverse events leading to dose reduction, interruption, or withdrawal.
Pharmaceuticals
Project
anticipates the submission of the sNDA for REZZAYO in the prophylaxis indication in Q3 of this year, following positive preliminary top-line results from the phase III ReSPECT study evaluating REZZAYO for prophylaxis of invasive fungal disease in adult immunosuppressed patients undergoing allogeneic bone and marrow transplant. Assuming timely submission and FDA acceptance, the company anticipates agency action in H1 of 2027.
Medical Research, Pharmaceuticals
Earnings
Earnings, Spending/Investment, Research & Development, Clinical Operations, Finance
CorMedix News & Media
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8 – 10, 2026.CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
CorMedix Inc. (CRMD) Q2 2026 Earnings Call August 13, 2026 8:30 AM EDTCompany ParticipantsJoseph Todisco - CEO & Chairman of the Board of...CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026, and will host a corporate update conference call at 8:30am Eastern Time.CorMedix Inc. (CRMD) Reports Q1 2026 Results
CorMedix Inc. (NASDAQ:CRMD) is one of the 10 Most Profitable Small Cap Stocks to Buy. On May 14, 2026, CorMedix Inc. (NASDAQ:CRMD) reported Q1 net revenue of $127.4 million and net income of $38.6 million with adjusted EBITDA of $70.0 million. The firm said DefenCath contributed $97.5 million in revenue with higher outpatient dialysis utilization […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CorMedix
Sign Up For FreeTo access detailed company insights
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections... Read More
